Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 46.18
+0.55 (1.21%)
Feb 3, 2026, 3:04 PM CST
SHE:002294 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,150 | 3,910 | 3,280 | 3,401 | 3,020 | 2,731 |
Other Revenue | 102.73 | 102.73 | 85.67 | 81.27 | 38.73 | 7.07 |
| 4,252 | 4,012 | 3,365 | 3,482 | 3,058 | 2,739 | |
Revenue Growth (YoY) | 8.76% | 19.22% | -3.35% | 13.85% | 11.68% | -38.74% |
Cost of Revenue | 1,102 | 1,138 | 1,065 | 1,001 | 811.29 | 847.87 |
Gross Profit | 3,150 | 2,874 | 2,300 | 2,481 | 2,247 | 1,891 |
Selling, General & Admin | 1,911 | 1,745 | 1,302 | 1,332 | 1,340 | 1,187 |
Research & Development | 477.64 | 421.24 | 409.19 | 533.75 | 357.37 | 371.2 |
Other Operating Expenses | 21.73 | 18.76 | 20.2 | 46.93 | 44.98 | 34.67 |
Operating Expenses | 2,422 | 2,190 | 1,734 | 1,916 | 1,743 | 1,584 |
Operating Income | 728.37 | 683.93 | 565.82 | 565.58 | 504.3 | 306.3 |
Interest Expense | -18.2 | -16.17 | -17.37 | -12.54 | -10.53 | -17.57 |
Interest & Investment Income | 96.42 | 80.09 | 80.94 | 151.26 | 181.9 | 35.5 |
Currency Exchange Gain (Loss) | 1.69 | 1.69 | 3.01 | 5.55 | -5.78 | -5.35 |
Other Non Operating Income (Expenses) | -3.67 | -1.37 | -0.43 | -5.84 | -7.54 | -21.46 |
EBT Excluding Unusual Items | 804.6 | 748.17 | 631.96 | 704 | 662.35 | 297.43 |
Impairment of Goodwill | - | - | -49.61 | -26.61 | - | -282.72 |
Gain (Loss) on Sale of Investments | 14.27 | 14.51 | 8.09 | 3.81 | - | -26.78 |
Gain (Loss) on Sale of Assets | -1.44 | -0.15 | -0.48 | -0.18 | -1.3 | 0.21 |
Asset Writedown | -138.12 | -159.64 | -2.89 | -24.06 | -131.6 | -1.59 |
Other Unusual Items | 29.62 | 29.62 | 54.68 | 56.76 | 70.39 | 70.21 |
Pretax Income | 708.93 | 632.52 | 641.76 | 713.73 | 599.84 | 56.74 |
Income Tax Expense | 24.46 | 27.36 | 60.93 | 79.36 | 71.52 | 6.61 |
Earnings From Continuing Operations | 684.46 | 605.16 | 580.83 | 634.37 | 528.32 | 50.13 |
Minority Interest in Earnings | -11.9 | -3.59 | -0.76 | 2.73 | 5.41 | 10.73 |
Net Income | 672.56 | 601.57 | 580.07 | 637.09 | 533.73 | 60.86 |
Net Income to Common | 672.56 | 601.57 | 580.07 | 637.09 | 533.73 | 60.86 |
Net Income Growth | 10.15% | 3.71% | -8.95% | 19.37% | 776.90% | -91.49% |
Shares Outstanding (Basic) | 1,121 | 1,114 | 1,116 | 1,098 | 1,067 | 1,014 |
Shares Outstanding (Diluted) | 1,121 | 1,114 | 1,116 | 1,098 | 1,067 | 1,014 |
Shares Change (YoY) | 0.88% | -0.13% | 1.55% | 2.90% | 5.23% | -3.55% |
EPS (Basic) | 0.60 | 0.54 | 0.52 | 0.58 | 0.50 | 0.06 |
EPS (Diluted) | 0.60 | 0.54 | 0.52 | 0.58 | 0.50 | 0.06 |
EPS Growth | 9.19% | 3.85% | -10.35% | 16.00% | 733.33% | -91.18% |
Free Cash Flow | 213.34 | 561.45 | 168.44 | 371.84 | 702.48 | 731.86 |
Free Cash Flow Per Share | 0.19 | 0.50 | 0.15 | 0.34 | 0.66 | 0.72 |
Dividend Per Share | 0.500 | 0.500 | 0.500 | 0.500 | 0.400 | - |
Dividend Growth | - | - | - | 25.00% | - | - |
Gross Margin | 74.09% | 71.64% | 68.34% | 71.26% | 73.47% | 69.04% |
Operating Margin | 17.13% | 17.05% | 16.81% | 16.24% | 16.49% | 11.19% |
Profit Margin | 15.82% | 14.99% | 17.24% | 18.30% | 17.45% | 2.22% |
Free Cash Flow Margin | 5.02% | 13.99% | 5.00% | 10.68% | 22.97% | 26.72% |
EBITDA | 1,114 | 1,045 | 893.22 | 873.67 | 798.4 | 552.33 |
EBITDA Margin | 26.19% | 26.03% | 26.54% | 25.09% | 26.11% | 20.17% |
D&A For EBITDA | 385.51 | 360.6 | 327.4 | 308.09 | 294.1 | 246.03 |
EBIT | 728.37 | 683.93 | 565.82 | 565.58 | 504.3 | 306.3 |
EBIT Margin | 17.13% | 17.05% | 16.81% | 16.24% | 16.49% | 11.19% |
Effective Tax Rate | 3.45% | 4.33% | 9.50% | 11.12% | 11.92% | 11.64% |
Revenue as Reported | 4,252 | 4,012 | 3,365 | 3,482 | 3,058 | 2,739 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.